SLC5A2 and metastatic malignant neoplasm: Specifically, this NMA aims to (1) compare the preventive efficacy of GLP-1 receptor agonists and SGLT2 inhibitors against metastatic cancers; (2) identify the most effective agents for prevention; (3) evaluate their relative safety profiles in preventive applications; and (4) provide evidence-based recommendations for future preventive strategies.